IMMIX BIOPHARMA INC. - COMMON STOCK

Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential

23 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

10 мар 2023 19:45:20 Источник Nasdaq GlobeNewswire

ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14

06 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire

Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission

27 фев 2023 08:45:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.

15 фев 2023 08:30:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting

09 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire

Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer

07 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire

Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

13 янв 2023 08:00:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached

06 янв 2023 08:00:00 Источник Nasdaq GlobeNewswire

Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting

28 дек 2022 08:00:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

20 дек 2022 08:00:00 Источник Nasdaq GlobeNewswire

ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors

19 дек 2022 08:00:00 Источник Nasdaq GlobeNewswire

Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

14 дек 2022 08:00:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

13 дек 2022 08:00:01 Источник Nasdaq GlobeNewswire

ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

12 дек 2022 08:00:01 Источник Nasdaq GlobeNewswire

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher

11 ноя 2022 08:00:00 Источник Nasdaq GlobeNewswire

Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26

25 окт 2022 08:00:32 Источник Nasdaq GlobeNewswire

ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

18 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire

ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

07 сен 2022 12:05:34 Источник Nasdaq GlobeNewswire

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

20 май 2022 08:47:35 Источник Nasdaq GlobeNewswire